1. Pilot Study Comparing Systemic and Tissue Pharmacokinetics of Irinotecan and Metabolites after Hepatic Drug-Eluting Chemoembolization
- Author
-
Elliot Levy, Aradhana M. Venkatesan, Julie A. Peretti, Michael S. Hughes, Tim F. Greten, Bradford J. Wood, Prakash K. Pandalai, Cody J. Peer, Charisse Garcia, William D. Figg, Andrew L. Lewis, and Tristan M. Sissung more...
- Subjects
Adult ,Male ,Drug ,medicine.medical_specialty ,Genotype ,Pharmacogenomic Variants ,media_common.quotation_subject ,Pilot Projects ,Ugt1a1 polymorphism ,Irinotecan ,Models, Biological ,digestive system ,Gastroenterology ,Article ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Text mining ,Pharmacokinetics ,Internal medicine ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Prospective Studies ,Chemoembolization, Therapeutic ,Glucuronosyltransferase ,Aged ,media_common ,business.industry ,Liver Neoplasms ,Area under the curve ,Middle Aged ,Pharmacogenomic Testing ,Phenotype ,Treatment Outcome ,030220 oncology & carcinogenesis ,Mutation ,Female ,Drug Monitoring ,Topoisomerase I Inhibitors ,Cardiology and Cardiovascular Medicine ,business ,Drug metabolism ,medicine.drug - Abstract
Differences in drug metabolism associated with UGT1A1 polymorphism could result in individualized local response to hepatic chemoembolization with irinotecan-eluting beads (DEBIRI) or predictable toxicities. Five patients with inoperable hepatic metastases from colorectal or anal malignancies treated with DEBIRI were assessed for UGT1A1 mutations. No difference in area under the curve (AUC) for SN38 in normal liver and tumor tissue samples was noted with variant or wild-type UBT1A1 (P = .16 and P = .05, respectively). Plasma SN-38 AUC was significantly lower in wild-type compared to variant patients (P < .0001). UGT1A1 genotype may not be predictive of hematologic toxicity after DEBIRI. more...
- Published
- 2019
- Full Text
- View/download PDF